Warfarin Therapy: Influence of Pharmacogenetic and Environmental Factors on the Anticoagulant Response to Warfarin

Vitamins and Hormones

Volumn 78, Issue , 2008, Pages 247-264

  Siguret, Virginie ^a,b   Pautas, Eric ^a,b   Gouin Thibault, Isabelle ^a  

^a HÔPITAL CHARLES FOIX   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; CYP2C9 PROTEIN, HUMAN; MENADIONE EPOXIDASE; MIXED FUNCTION OXIDASE; UNCLASSIFIED DRUG; UNSPECIFIC MONOOXYGENASE; VITAMIN K GROUP; WARFARIN;

BLOOD CLOTTING; DRUG ANTAGONISM; ENVIRONMENT; GENETICS; HUMAN; PHARMACOGENETICS; PHYSIOLOGY; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM;

ANTICOAGULANTS; ARYL HYDROCARBON HYDROXYLASES; BLOOD COAGULATION; ENVIRONMENT; HUMANS; MIXED FUNCTION OXYGENASES; PHARMACOGENETICS; POLYMORPHISM, SINGLE NUCLEOTIDE; VITAMIN K; WARFARIN;

EID: 40949092617     PISSN: 00836729     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S0083-6729(07)00012-X     Document Type: Review

References (58)

1. Aithal G.P., Day C.P., Kesteven P.J., and Daly A.K. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet 353 (1999) 717-719
2. Ang-Lee M., Moss J., and Yuan C.S. Herbal medicines and perioperative care. JAMA 286 2 (2001) 208-216
3. Ansell J., Hirsh J., Poller L., Bussey H., Jacobson A., and Hylek E. The pharmacology and management of the vitamin K antagonists: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126 3 Suppl (2004) 204S-233S
4. Berkner K.L. The vitamin K-dependent carboxylase. Annu. Rev. Nutr. 25 (2005) 127-149
5. Bodin L., Horellou M.H., Flaujac C., Loriot M.A., and Samama M.M. A vitamin K epoxide reductase comples subunit-1 (VKORC1) mutation in a patient with vitamin K antagonist resistance. J. Thromb. Haemost. 3 (2005) 1533-1535
6. Booth S.L., Charnley J.M., Sadowski J.A., Saltzman Z., Bovill E.G., and Cushman M. Dietary vitamin K1 and stability of oral anticoagulation : Proposal of a diet with constant vitamin K1 content. Thromb. Haemost. 77 (1997) 504-509
7. Couris R., Tataronis G., McCloskey W., Oertel L., Dallal G., Dwyer J., and Blumberg J.B. Dietary vitamin K variability affects international normalized ratio (INR) coagulation indices. Int. J. Vitam. Nutr. Res. 76 (2006) 65-74
8. Crowther M.M., Douketis J.D., Schnurr T., Steidl L., Mera V., Ultori C., Venco A., and Ageno W. Oral vitamin K1 lowers the international normalized ratio more rapidly than subcutaneous vitamin K1 in the treatment of warfarin-associed coagulopathy. Ann. Intern. Med. 137 (2002) 251-254
9. Cushman M., Booth S.L., Possidente C.J., Davidson K.W., Sadowski J.A., and Bovill E.G. The association of vitamin K status with warfarin sensitivity at the onset of treatment. Br. J. Haematol. 112 (2001) 572-577
10. Custodio das Dores S.M., Booth S.L., Martini L.A., de Carvalho Gouvea V.H., Padovani C.R., de Abreu Maffei F.H., Campana A.O., and Rupp de Paiva S.A. Relationship between diet and anticoagulant response to warfarin. Eur. J. Nutr. 46 3 (2007) 147-154
11. Dam H. The antihaemorrhagic vitamin of the chick. Biochem. J. 29 (1935) 1273-1285
12. D'Andrea G., D'Ambrosio R.L., Di Perna P., Chetta M., Santacroce R., Brancaccio V., Grandone E., and Margaglione M. A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin. Blood 105 (2004) 645-649
13. Fasco M.J., Principe L.M., Walsh W.A., and Friedman P.A. Warfarin inhibition of vitamin K 2,3 epoxide reductase in rat liver microsomes. Biochemistry 22 (1983) 5655-5660
14. Franco V., Polanczyk C.A., Clausell N., and Rohde L.E. Role of dietary vitamin K intake in chronic oral anticoagulation: Prospective evidence from observational and randomized protocols. Am. J. Med. 116 (2004) 651-656
15. Gage B.F. Pharmacogenetics-based coumarin therapy. Hematology 46 (2006) 7-473
16. Gage B.F., Eby C., Milligan P.E., Banet G.A., Duncan J.R., and McLeod H.L. Use of pharmacogenetics and clinical factors to predict the maintenance dose of warfarin. Thromb. Haemost. 91 1 (2004) 87-94
17. Hanley J.P. Warfarin reversal. J. Clin. Pathol. 57 (2004) 1132-1139
18. Higashi M.K., Veenstra D.L., Kondo L.M., Wittkowsky A.K., Srinouanprachanh S.L., Farin F.M., and Rettie A.E. Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. JAMA 287 (2002) 1690-1698
19. Holbrook A.M., Pereira J.A., Labiris R., Mcdonald H., Douketis J.D., Crowther M., and Wells P.S. Systematic overview of warfarin and its drug and food interactions. Arch. Intern. Med. 165 (2005) 1095-1106
20. Hylek E.M. Oral anticoagulants. Pharmacologic issues for use in the elderly. Clin. Geriatr. Med. 17 1 (2001) 1-13
21. Jacobs L.G. Warfarin pharmacology clinical management and evaluation of hemorrhagic risk for the elderly. Clin. Geriatr. Med. 22 (2006) 17-32
22. Jiang X., Blair E.Y.L., and McLachlan A. Investigation of the effects of herbal medicines on warfarin response in healthy subjects: A population pharmacokinetic pharmacodynamic modeling approach. J. Clin. Pharmacol. 46 (2006) 1370-1378
23. Kamali F., Khan T.I., King B.P., Frearson R., Kesteven P., Wood P., Daly A.K., and Wynne H. Contribution of age and body size and CYP2C9 genotype to anticoagulant. Clin. Pharmacol. Ther. 75 (2004) 204-212
24. Khan T., Wynne H., Wood P., Torrance A., Hankey C., Avery P., Kesteven P., and Kamali F. Dietary vitamin K influences intra-individual variability in anticoagulant response to warfarin. Br. J. Haematol. 124 (2004) 348-354
25. Kirchheiner J., and Brockmöller J. Clinical consequences of cytochrome P450 2C9 polymorphisms. Clin. Pharmacol. Ther. 77 (2005) 1-16
26. Kurnik D., Loebstein R., Rabinovitz H., Austerweil N., Halkin H., and Almog S. Over the counter citamin K containing multivitamin supplements disrups warfarin anticoagulation in vitamin K depleted patients. Thromb. Haemost. 92 5 (2004) 1018-1024
27. Li T., Chang C.Y., Jin D.Y., Lin P.J., Khvorova A., and Stafford D.W. Identification of the gene for vitamin K epoxide reductase. Nature 427 (2004) 541-544
28. Linder M.W., Looney S., Adams J.E., Johnson N., Antonino-Green D., Lacefield N., Bukaveckas B.L., and Valdes J.R. Warfarin dose adjustments based on CYP2C9 genetic polymorphisms. J. Thromb. Haemost. 14 3 (2002) 227-232
29. Loebstein R., Yonath H., Peleg D., Almog S., Rotenberg M., Lubetsky A., Roitelman J., Harats D., Halkin H., and Ezra D. Interindividual variability in sensitivity to warfarin Nature or nurture?. Clin. Pharmacol. Ther. 70 (2001) 159-164
30. Lubetsky A., Dekel-Stern E., Chetrit A., Lubin F., and Halkin H. Vitamin K intake and sensitivity to warfarin in patients consuming regular diets. Thromb. Haemost. 81 (1999) 396-399
31. Mahé I., Bertrand N., Drouet L., Simoneau G., Mazoyer E., Bal dit Sollier C., Caulin C., and Bergmann J.F. Paracetamol: A haemorrhagic risk factor in patients on warfarin. Br. J. Clin. Pharmacol. 59 (2005) 371-374
32. Margaglione M., Colaizzo D., D'Andrea G., Brancaccio V., Ciampa A., Grandone E., and Di Minno G. Genetic modulation of oral anticoagulation with warfarin. Thromb. Haemost. 84 (2000) 775-778
33. Panneerselvam S., Baglin C., Lefort W., and Baglin T. Analysis of risk factors for over-anticoagulation in patients receiving long-term warfarin. Br. J. Haematol. 103 2 (1998) 422-424
34. Pautas E., Gouin-Thibault I., Debray M., Gaussem P., and Siguret V. Haemorrhagic complications of vitamin K antagonists in the elderly. Drugs Aging 23 (2004) 13-25
35. Pedersen F.M., Hamberg O., Hess K., and Ovesen L. The effect of dietary vitamin K on warfarin-induced anticoagulation. J. Intern. Med. 229 (1991) 517-520
36. Penning-van Beest F.J., van Meegen E., Rosendaal F.R., and Stricker B.H. Characteristics of anticoagulant therapy and comorbidity related to overanticoagulation. Thromb. Haemost. 86 (2001) 569-574
37. Peyvandi F., Spreafico M., Siboni S.M., Moia M., and Mannuccio Mannucci P. CYP2C9 genotypes and dose requirements during the induction phase of oral anticoagulant therapy. Clin. Pharmacol. Ther. 75 3 (2004) 198-203
38. Redwood M., Taylor C., Bain B.J., and Matthews J.H. The association of age with dosage requirement for warfarin. Age Ageing 20 3 (1991) 217-220
39. Reese A.M., Farnett L.E., Lyons R.M., Patel B., Morgan L., and Bussey H.I. Low-dose vitamin K to augment anticoagulation control. Pharmacotherapy 25 12 (2005) 1746-1751
40. Rieder M.J., Reiner A.P., Gage B.F., Nickerson D.A., Eby C.S., McLeod H.L., Bough D.K., Thummel K.E., Veenstra D.L., and Rettie A.E. Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N. Engl. J. Med. 352 (2005) 2285-2293
41. Rohde L.E., de Assis C.S., and Rabelo E.R. Dietary vitamin K intake and coagulation in elderly patients. Curr. Opin. Clin. Nutr. Metab. Care 10 (2007) 1-5
42. Rost S., Fregin A., Ivaskevicius V., Conzelmann E., Hortnagel K., Pelz H.J., Lappegard K., Seifried E., Scharrer I., Tuddenham E.G., Muller C.R., Strom T.M., et al. Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2. Nature 427 (2004) 537-541
43. Samuels N. Herbal remedies and anticoagulant therapy. Thromb. Haemost. 93 1 (2005) 1-7
44. Schurgers L.J., Shearer M.J., Hamulyak K., Stöcklin E., and Vermeer C. Effect of vitamin K intake on the stability of oral anticoagulant treatment: Dose-response relationships in healthy subjects. Blood 104 (2004) 2682-2689
45. Sconce E., Khan T., Mason J., Noble F., Wynne H., and Kamali F. Patients with unstable control have a poorer dietary intake of vitamin K compared to patients with stable control of anticoagulation. Thromb. Haemost. 93 5 (2005) 799-800
46. Sconce E.A., Khan T.I., Wynne H.A., Avery P., Monkhouse L., King B.P., Wood P., Kesteven P., Daly A.K., and Kamali F. The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: Proposal for a new dosing regimen. Blood 106 (2005) 2329-2333
47. Sconce E., Avery P., Wynne H., and Kamali F. Vitamin K supplementation can improve stability of coagulation for patients with unexplained variability in response to warfarin. Blood 109 6 (2007) 2419
48. Scordo M.G., Pengo V., Spina E., Dahl M.L., Gusella M., and Padrini R. Influence of CYP2C9 and CYP2C19 genetic polymorphisms on warfarin maintenance dose and metabolic clearance. Clin. Pharmacol. Ther. 72 (2002) 702-710
49. Siguret V., Gouin I., Golmard J.L., Geoffroy S., Andreux J.P., and Pautas E. Polymorphismes du cytochrome P450 2C9 (CYP2C9) et posologie à l'équilibre pour des patients âgés traités par warfarine. Rev. Med. Interne 25 (2004) 271-274
50. Siguret V., Gouin I., Debray M., Perret-Guillaume C., Boddaert J., Mahé I., Donval V., Seux M., Romain-Pilotaz M., Gisselbrecht M., Verny M., and Pautas E. Initiation of warfarin therapy in elderly medical inpatients: A safe and accurate regimen. Am. J. Med. 118 (2005) 137-142
51. Sorano G.G., Biondi G., Conti M., Mameli G., Licheri D., and Marongiu F. Controlled vitamin K content diet for improving the management of poorly controlled anticoagulated patients: A clinical practice proposal. Haemostasis 23 2 (1993) 77-82
52. Stafford D.W. The vitamin K cycle. J. Thromb. Haemost. 3 (2005) 1873-1878
53. Takahashi H., and Echizen H. Pharmacogenetics of warfarin elimination and its clinical implications. Clin. Pharmacokinet. 40 (2001) 587-603
54. Taube J., Halsall D., and Baglin T. Influence of cytochrome P-450 CYP2C9 polymorphisms on warfarin sensitivity and risk of over-anticoagulation in patients on long-term treatment. Blood 96 (2000) 1816-1819
55. Veenstra D.L., You J.H.S., Rieder M.J., Farin F.M., Wilkerson H.W., Blough D.K., Cheng G., and Rettie A. Association of vitamin K epoxide reductase complex 1 (VKORC1) variants with warfarin dose in a Hong Kong Chinese patient population. Pharmacogenet. Genomics 15 (2005) 687-691
56. Visser L.E., van Schaik R.H., van Vliet M., Trienekens P.H., De Smet P.A., Vulto A.G., Hofman A., van Duijn C.M., and Stricker B.H. The risk of bleeding complications in patients with cytochrome P450 CYP2C9*2 or CYP2C9*3 alleles on acenocoumarol or phenprocoumon. Thromb. Haemost. 92 (2004) 61-66
57. Voora D., Eby C., Linder M.W., Milligan P.E., Bukaveckas B.L., McLeod H.L., Maloney W., Clohisy J., Burnett R.S., Grosso L., Gatchel S.K., and Gage B.F. Prospective dosing of warfarin based on cytochrome P-450 2C9 genotype. Thromb. Haemost. 93 (2005) 700-705
58. Wallin R., and Hutson S.M. Warfarin and the vitamin K-dependent γ-carboxylation system. Trends Mol. Med. 10 (2004) 299-302